# EDGAR Filing Document

**Accession Number:** 0001041024
**File Stem:** 0001104659-25-078594
**Filing Date:** 2025-8
**Character Count:** 18725
**Document Hash:** 1bc9fd5d3d036bb2a5b234d7e5a84be2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-078594.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001104659-25-078594

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**EFFECTIVENESS DATE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ROCKWELL MEDICAL, INC.
- **CENTRAL INDEX KEY:** 0001041024
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 383317208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289604
- **FILM NUMBER:** 251219118

**BUSINESS ADDRESS:**
- **STREET 1:** 30142 WIXOM ROAD
- **CITY:** WIXOM
- **STATE:** MI
- **ZIP:** 48393
- **BUSINESS PHONE:** 8004493353

**MAIL ADDRESS:**
- **STREET 1:** 30142 WIXOM ROAD
- **CITY:** WIXOM
- **STATE:** MI
- **ZIP:** 48393

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20120530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL, INC.
- **DATE OF NAME CHANGE:** 20120525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ROCKWELL MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970722

**As filed with the Securities and Exchange Commission on August 14, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

 ****

**ROCKWELL MEDICAL, INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **38-3317208** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification Number)** |

---

**30142 S. Wixom Road<br> Wixom, Michigan 48393**

**(248) 960-9009**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan**

**(Full title of the plans)**

------

**Mark Strobeck, Ph.D.**

**President and Chief Executive Officer**

**Rockwell Medical, Inc.**

**30142 S. Wixom Road**

**Wixom, Michigan 48393**

**(248) 960-9009**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

**Copies to:**

---

| | |
|:---|:---|
| **Ryan A. Murr<br> Gibson, Dunn & Crutcher LLP<br> One Embarcadero Center, Suite 2600<br> San Francisco, CA 94111<br> (415) 393-8200** | **Megan C. Timmins<br> EVP, Chief Legal Officer and Secretary<br> Rockwell Medical, Inc.<br> 30142 S. Wixom Road<br> Wixom, Michigan 48393<br> (248) 960-9009** |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed to register an additional 5,000,000 shares of Rockwell Medical, Inc. (the "Company" or the "Registrant") common stock, par value $0.0001, issuable under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. The information contained in the Registrant's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on September 14, 2018 ([File No. 333-227365](https://www.sec.gov/Archives/edgar/data/1041024/000110465918056948/a18-28135_1s8.htm)), June 2, 2020 ([File No. 333-238889](https://www.sec.gov/Archives/edgar/data/1041024/000162828020008834/rmti-20200521xs8xltipadded.htm)), August 16, 2022 ([File No. 333-266892](https://www.sec.gov/Archives/edgar/data/1041024/000119312522221411/d308421ds8.htm)), and August 15, 2023 ([File No. 333-273985](https://www.sec.gov/Archives/edgar/data/1041024/000110465923091559/tm2323578d1_s8.htm)), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.

**Item 8.** **Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1041024/000110465919048258/a19-18069_2ex3d3.htm) | [Certificate of Incorporation, effective as of August 30, 2019 (incorporated by reference to Exhibit 3.3 to the Company's Form 8-K filed August 30, 2019).](https://www.sec.gov/Archives/edgar/data/1041024/000110465919048258/a19-18069_2ex3d3.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1041024/000110465922060314/tm2215543d1_ex3-1.htm) | [Certificate of Amendment to Certificate of Incorporation of Rockwell Medical, Inc., dated May 12, 2022 (incorporated by reference to Exhibit 3.1 to the Company's Form 8-K filed May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1041024/000110465922060314/tm2215543d1_ex3-1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1041024/000162828022029627/amendedandrestatedbylawsex.htm) | [Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q filed November 14, 2022).](https://www.sec.gov/Archives/edgar/data/1041024/000162828022029627/amendedandrestatedbylawsex.htm) |
| [5.1\*](tm2522781d1_ex5-1.htm) | [Opinion of Gibson, Dunn & Crutcher LLP.](tm2522781d1_ex5-1.htm) |
| [23.1\*](tm2522781d1_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm.](tm2522781d1_ex23-1.htm) |
| [23.2\*](tm2522781d1_ex5-1.htm) | [Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1).](tm2522781d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney (included in signature page to this Registration Statement)](#a_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1041024/000104102425000011/rmti-20250630x10qex101eip.htm) | [Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q filed August 14, 2025).](https://www.sec.gov/Archives/edgar/data/1041024/000104102425000011/rmti-20250630x10qex101eip.htm) |
| [107.1\*](tm2522781d1_ex-filingfees.htm) | [Calculation of Filing Fee Table.](tm2522781d1_ex-filingfees.htm) |

---

\*Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wixom, State of Michigan, on this 14th day of August, 2025.

---

| | |
|:---|:---|
| **ROCKWELL MEDICAL, INC.** | **ROCKWELL MEDICAL, INC.** |
| By: | /s/ Mark Strobeck |
|  | Name: Mark Strobeck, Ph.D. |
|  | Title: President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Strobeck, Ph.D. and Megan Timmins, and each of them acting individually, as his or her attorney-in-fact, with full power of substitution, for him or her and in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto) and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name and Signature** | **Title** | **Date** |
| /s/ Mark Strobeck | President, Chief Executive Officer and Director | August 14, 2025 |
| **Mark Strobeck, Ph.D.** | (Principal Executive Officer) |  |
| /s/ Jesse Neri | Senior Vice President, Chief Financial Officer | August 14, 2025 |
| **Jesse Neri** | (Principal Financial Officer) |  |
| /s/ Nicholas Fanslau | Controller | August 14, 2025 |
| **Nicholas Fanslau** | (Principal Accounting Officer) |  |
| /s/ Robert S. Radie | Director and Chairman of the Board | August 14, 2025 |
| **Robert S. Radie** |  |  |
| /s/ John G. Cooper | Director | August 14, 2025 |
| **John G. Cooper** |  |  |
| /s/ Joan Lau | Director | August 14, 2025 |
| **Joan Lau, Ph.D.** |  |  |
| /s/ Allen Nissenson | Director | August 14, 2025 |
| **Allen Nissenson, M.D.** |  |  |
| /s/ Mark H. Ravich | Director | August 14, 2025 |
| **Mark H. Ravich** |  |  |
| /s/ Andrea Heslin Smiley | Director | August 14, 2025 |
| **Andrea Heslin Smiley** |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm2522781d1_ex5-1img001.jpg)

August 14, 2025

Rockwell Medical, Inc.<br> 30142 S. Wixom Road<br> Wixom, Michigan 48393

Re: *Registration Statement on Form S-8*

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "Registration Statement") of Rockwell Medical, Inc., a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to 5,000,000 shares of the Company's Common Stock, par value $0.0001 per share (the "Shares"). The Shares subject to the Registration Statement are to be issued under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan (the "Plan").

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinion set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to this opinion, we have relied to the extent we deemed appropriate and without independent investigation upon statements and representations of officers and other representatives of the Company and others. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plan that would expand, modify or otherwise affect the terms of the Plan or the respective rights or obligations of the participants thereunder.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor in accordance with the terms set forth in the Plan as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson, Dunn & Crutcher LLP

**Gibson, Dunn & Crutcher LLP**

One Embarcadero Center Suite 2600 \| San Francisco, CA 94111-3715 \| T: Tel 415.393.8200 \| F: 415.393.8306\| gibsondunn.com

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of Rockwell Medical, Inc. on Form S-8 to be filed on or about August 14, 2025 of our report dated March 20, 2025, on our audit of the financial statements as of December 31, 2024 and 2023 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed March 20, 2025.

*/s/ EisnerAmper LLP*

EISNERAMPER LLP

Iselin, New Jersey

August 14, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **ROCKWELL MEDICAL, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.0001 per share | 457(a) | 5000000 | $1.00 | $5000000.00 | 0.0001531 | $765.50 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $5000000.00  |  | $765.50  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $765.50  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional securities that may be offered or issued in respect of the securities registered by this Registration Statement to prevent dilution as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. (2) This Registration Statement registers 5,000,000 additional shares of common stock, par value $0.0001 per share (the "Common Stock"), of Rockwell Medical, Inc. available for issuance under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. The "Proposed Maximum Offering Price Per Unit" and the "Maximum Aggregate Offering Price" are estimated in accordance with Rules 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $1.00 per share, which represents the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on August 7, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---